AbbVie Inc. acquires ImmunoGen, Inc. for USD 10,100,000,000 (2023)

Deal facts

Buyer: AbbVie Inc.
Target: ImmunoGen, Inc.
Deal value: USD 10,100,000,000
Announced: 30 November 2023
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

12 Feb 2024CompletedClosed
AbbVie Inc. completes acquisition of ImmunoGen, Inc.
Introductory Note. As previously disclosed, on November 30, 2023, ImmunoGen, Inc., a Massachusetts corporation (the “Company” or “ImmunoGen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with AbbVie Inc., a Delaware corporation (“AbbVie”), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie (“Intermediate Sub”), and Athene Mer
Source

OpinionExit Mode editorial

The acquisition of ImmunoGen by AbbVie for ten point one billion dollars in cash stands as a definitive signal for the biotechnology sector. We see this as a clear move by a major pharmaceutical player to secure critical antibody-drug conjugate capabilities without the friction of public market scrutiny. The deal, announced in late November 2023 and now completed, removes the target from the public sphere entirely. This going-private transaction is executed purely through cash consideration, which eliminates the uncertainty often associated with stock-based swaps or complex earn-out structures. For the SME founder watching from the UK, the mechanics here are instructive. A full cash exit provides immediate liquidity and a clean break, avoiding the prolonged integration risks that often plague mixed-consideration deals.

The strategic rationale is evident in the sector dynamics. AbbVie is not merely buying a company; it is acquiring a specific technological platform to bolster its oncology pipeline. When a buyer of this scale moves to take a target private, they are often signalling that the asset requires a longer development horizon than public investors typically tolerate. This shift allows the new owner to focus on regulatory pathways and clinical trials without the quarterly earnings pressure that can derail long-term science. The transaction bypasses the need for a prospectus or shareholder vote that would be required in a public-to-public merger, streamlining the path to completion. While US competition law applies, the specific nature of this acquisition suggests the parties have navigated the necessary anti-trust thresholds to secure clearance.

We believe this deal underscores a broader trend where large corporates are willing to pay a premium for certainty and control. The decision to go private rather than merge on public terms suggests the buyer values the ability to restructure the target's operations without external interference. This is a crucial distinction for founders who might otherwise fear losing their strategic direction in a public merger. The cash nature of the deal also implies that the buyer has the balance sheet strength to absorb the cost without needing to issue new equity, which can dilute existing shareholders. This approach protects the value of the deal for the target's stakeholders and ensures a swift transfer of ownership.

For the founder preparing their own exit, the lesson is to prioritise deal certainty over headline valuation complexity. If your technology requires a long-term view that public markets cannot support, a private buyer offering an all-cash deal may be the superior route to liquidity. This week, you should review your current cap table and identify which potential buyers have the cash reserves to offer a clean, all-cash exit without relying on stock swaps or deferred payments.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2023 deals More going private deals More from AbbVie Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history

AbbVie Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive

AbbVie Inc. to acquire ImmunoGen, Inc.

Deal facts

Join Exit Mode Insider

Deal timeline

Browse adjacent archives

Similar deals

Merck to acquire Terns Pharmaceuticals, Inc.

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

Servier to acquire Day One Biopharmaceuticals, Inc.

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Abbott to acquire Exact Sciences Corp

AbbVie Inc.

How this page is built